CME in Minutes: Education in Oncology & Hematology
Kathleen Moore, MD, MS - Targeting Disease Progression in Advanced Ovarian Cancer: Can Combination PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes?
31 Aug 2022
Please visit answersincme.com/AXF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic cancers discusses the potential role of combination poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors (ICIs) in improving outcomes in advanced ovarian cancer.Upon completion of this activity, participants should be better able to: Discuss the clinical rationale for combining PARP inhibitors with ICIs; Review the clinical profile of PARP inhibitors in combination with ICIs for patients with advanced ovarian cancer; and Identify the potential place in therapy for PARP inhibitors in combination with ICIs in advanced ovarian cancer.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana